Something else that hasn't been mentioned is the significant cost of running trials. Halving the patients will be a massive expenditure not needeed. While highly unlikely to halve the cost, it could potentially save us a quarter or even a third of the original forecast expense as compared to what it would have cost a week ago. I think our q4 books are going to look pretty good.
Imugene - Charts & Price Action (New thread), page-831
-
- There are more pages in this discussion • 968 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
